SCHEMBL15026720

SCHEMBL15026720

Cc1cc(-c2n[nH]c(CC(C)C)n2)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.44
ADORA1 P30542 3/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
TRPV3 Q8NET8 1/20 0.39
NR1H2 P55055 2/20 0.39
TGFBR1 P36897 1/20 0.37
NR1H3 Q13133 1/20 0.37
ROCK2 O75116 1/20 0.37
CACNA1G O43497 1/20 0.36
CACNA1H O95180 1/20 0.36
CACNA1I Q9P0X4 1/20 0.36
GRIN2B Q13224 1/20 0.36
EGFR P00533 1/20 0.36
RET P07949 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5383966 0.89 CSNK1D (0.49) ADORA2AADORA1MAPK1TGFBR1ROCK2
SCHEMBL15026753 0.86 ADORA2A (0.42) ADORA2AADORA1RAB9ANPC1POLB
SCHEMBL15025603 0.84 TGFBR1 (0.47) ADORA2AADORA1RAB9ANPC1POLB
SCHEMBL15025491 0.82 AOC3 (0.46) ADORA2AADORA1RAB9ANPC1POLB
SCHEMBL2221940 0.81 RAB9A (0.44) RAB9ANPC1POLBMEN1MAPT
SCHEMBL15026752 0.80 DDX3X (0.43) ADORA2AADORA1RAB9ANPC1POLB
SCHEMBL5372338 0.79 CSNK1D (0.49) ADORA2AADORA1MAPK1ROCK2RET
SCHEMBL15025171 0.78 SUCNR1 (0.43) ADORA2AADORA1RAB9ANPC1POLB
SCHEMBL15025173 0.78 NPY2R (0.41) ADORA2AADORA1RAB9ANPC1MEN1
SCHEMBL5378295 0.78 CSNK1D (0.51) ADORA2AMAPK1ROCK2RETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889677-B2 Substituted triazoles useful as mGlu5 receptor modulators Boehringer Ingellheim International GmbH (DE) 2014-11-18 US disclosed
US-8642774-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-04 US disclosed
US-20130184248-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-18 US disclosed
US-20130150341-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150341-A1 NOVEL COMPOUNDS GRM5, GRM1, GRIK5 ADORA2A 79/4885ADORA1 77/4885RAB9A 732/4885
US-20130184248-A1 NOVEL COMPOUNDS GRM5, GRIN1, GRM1 ADORA2A 48/4885ADORA1 54/4885RAB9A 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.